Otonomy (OTIC) stock price, revenue, and financials

Otonomy market cap is $76 m, and annual revenue was $745 k in FY 2018

$76 M

OTIC Mkt cap, 12-Dec-2019

$125 K

Otonomy Revenue Q3, 2019
Otonomy Gross profit (Q3, 2019)-95 K
Otonomy Gross profit margin (Q3, 2019), %(76%)
Otonomy Net income (Q3, 2019)-10 M
Otonomy EBIT (Q3, 2019)-10.1 M
Otonomy Cash, 30-Sept-201916.3 M
Otonomy EV74.6 M

Otonomy Revenue

Otonomy revenue was $745 k in FY, 2018 which is a 39.7% year over year decrease from the previous period.

Embed Graph

Otonomy Income Statement

Otonomy Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018

Cash

24.2m18.5m33.6m

Accounts Receivable

91.0k107.0k108.0k

Inventories

1.4m6.0k

Current Assets

202.2m122.4m100.1m

PP&E

5.0m4.7m4.0m

Total Assets

208.6m128.4m105.0m

Accounts Payable

1.3m961.0k1.0m

Current Liabilities

15.2m8.2m7.5m

Long-term debt

14.8m

Total Debt

14.8m

Total Liabilities

15.9m11.1m25.3m

Additional Paid-in Capital

467.5m482.2m494.9m

Retained Earnings

(274.7m)(364.8m)(415.2m)

Total Equity

192.7m117.3m79.7m

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.1 x1.1 x1.3 x

Otonomy Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018

Net Income

(110.6m)(90.1m)(50.4m)

Depreciation and Amortization

708.0k1.3m1.2m

Accounts Receivable

(91.0k)(16.0k)(1.0k)

Inventories

(1.4m)153.0k

Accounts Payable

(2.2m)(398.0k)68.0k

Cash From Operating Activities

(94.3m)(75.3m)(38.4m)

Purchases of PP&E

(2.5m)(1.3m)(496.0k)

Cash From Investing Activities

(149.4m)69.0m38.0m

Cash From Financing Activities

109.2m1.1m15.2m

Interest Paid

4.0k

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(27.1m)(71.3m)(11.4m)(25.0m)(37.5m)(12.0m)(23.7m)(33.7m)

Depreciation and Amortization

923.0k295.0k594.0k892.0k276.0k565.0k854.0k

Accounts Receivable

178.0k76.0k(35.0k)(26.0k)93.0k62.0k94.0k40.0k75.0k

Inventories

1.2m1.2m197.0k6.0k

Accounts Payable

212.0k1.3m138.0k1.5m(184.0k)321.0k123.0k837.0k(90.0k)

Cash From Operating Activities

(60.9m)(9.8m)(20.1m)(28.1m)(10.5m)(19.3m)(29.6m)

Purchases of PP&E

(844.0k)(74.0k)(343.0k)(463.0k)(36.0k)(153.0k)(297.0k)

Cash From Investing Activities

53.6m14.5m20.4m30.3m(6.8m)(2.3m)12.2m

Cash From Financing Activities

549.0k32.0k229.0k229.0k(52.0k)69.0k71.0k

Net Change in Cash

(6.8m)4.8m570.0k2.5m(17.4m)(21.5m)(17.4m)

Interest Paid

347.0k698.0k1.0m

Otonomy Ratios

USDY, 2019

EV/EBIT

-7.4 x

EV/CFO

-2.5 x

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.8 x

Otonomy Operating Metrics

FY, 2016

Patents Issued

88

Patents Pending

115

Phase I Trials Products

1

Phase II Trials Products

2

Phase III Trials Products

2

Preclinical Phase Products

1

Products

1